Harry Raftopoulos - Concepedia

Author

Harry Raftopoulos

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

H Raftopoulos, H. Raftopoulos, HARRY RAFTOPOULOS, Harry Raftopoulos, Laszlo Radvanyi

Publications

9.5K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)South Texas Accelerated Research Therapeutics The Barbara Ann Karmanos Cancer Institute Massachusetts General Hospital Dana-Farber Cancer Institute

About

Harry Raftopoulos is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	1.9K
2	Health Sciences	6	6	190
3	Pathology	3	3	1.6K
4	Immunology	2	2	254
5	Microbiology	1	1	15

Harry Raftopoulos

Publications

9.1K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, The Lancet Oncology OncologyMetronomic TherapyPathologyBronchial NeoplasmOpen-label Keynote-021 Study	2016	1.4K
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy David Warr, Paul J. Hesketh, Richard J. Gralla, Journal of Clinical Oncology	2005	464
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist, Journal of Thoracic Oncology Advanced NsclcFirst-line TherapyMedicineImmunologyPathology	2018	175
Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy Jørn Herrstedt, Hyman B. Muss, David Warr, Cancer	2005	118
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Journal of Clinical Oncology Advanced NsclcFront-line TherapyMedicinePd-l1 25Pharmacology	2016	85
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Lung Cancer MedicinePathologyImmune Checkpoint InhibitorKeynote-021 StudyCancer Treatment	2018	79
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Lung Cancer MedicineImmunologyTumor ImmunityKeynote-021 Cohorts DImmune Checkpoint Inhibitor	2018	79
A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck Robert I. Haddad, Lisa J. Weinstein, Tad J. Wieczorek, Clinical Cancer Research	2004	66
Long-Term Transfer and Expression of the Human β-Globin Gene in a Mouse Transplant Model Harry Raftopoulos, Maureen Ward, Philippe Leboulch, Blood	1997	61

Page 1